Work

Engineered Vancomycin, with Increased Interactions with Peptidoglycan Stem Peptide, Conquers Non-tuberculosis Mycobacteria

Year: 2023

Type: editorial

Abstract: Vancomycin-like drugs target peptidoglycan (PG) via binding to C-terminal d -Ala- d -Ala dipeptide. An engineered vancomycin has enhanced affinity for the PG stem peptide, due to probable interactions with a third residue, meso -diaminopimelic acid, in the PG. This engineered vancomycin displays enhanced killing of mycobacteria.

Source: Journal of Medicinal Chemistry

DOI: 10.1021/acs.jmedchem.3c01219

Authors: Christopher Vennard, Temitope Oropo, Herman O. Sintim

Institution: Purdue University West Lafayette

Language: English

Topic: Microbial Natural Products and Biosynthesis

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Foundation for the National Institutes of Health, National Institute of Allergy and Infectious Diseases